Clinical Trials
14 trialsNCT04996706 2026-05-26
LEO
Mayo Clinic
Enrolling by invitation
NCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT07075185 2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT02690545 2026-01-06
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770037 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770102 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770544 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting